CN119487033A - 取代的咪唑并吡啶和咪唑并嘧啶，以及它们治疗、改善和/或预防视网膜变性的用途 - Google Patents
取代的咪唑并吡啶和咪唑并嘧啶，以及它们治疗、改善和/或预防视网膜变性的用途 Download PDFInfo
- Publication number
- CN119487033A CN119487033A CN202380050874.5A CN202380050874A CN119487033A CN 119487033 A CN119487033 A CN 119487033A CN 202380050874 A CN202380050874 A CN 202380050874A CN 119487033 A CN119487033 A CN 119487033A
- Authority
- CN
- China
- Prior art keywords
- certain embodiments
- compound
- compound according
- subject
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263338264P | 2022-05-04 | 2022-05-04 | |
| US63/338,264 | 2022-05-04 | ||
| US202263411405P | 2022-09-29 | 2022-09-29 | |
| US63/411,405 | 2022-09-29 | ||
| PCT/US2023/020978 WO2023215465A1 (en) | 2022-05-04 | 2023-05-04 | Substituted imidazopyridines and imidazopyrimidines, and use of same for treating, ameliorating, and/or preventing retinal degeneration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119487033A true CN119487033A (zh) | 2025-02-18 |
Family
ID=88647025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380050874.5A Pending CN119487033A (zh) | 2022-05-04 | 2023-05-04 | 取代的咪唑并吡啶和咪唑并嘧啶，以及它们治疗、改善和/或预防视网膜变性的用途 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250288588A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4519268A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025516315A (cg-RX-API-DMAC10.html) |
| CN (1) | CN119487033A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2023265523A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3251997A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023215465A1 (cg-RX-API-DMAC10.html) |
-
2023
- 2023-05-04 EP EP23800027.7A patent/EP4519268A1/en active Pending
- 2023-05-04 AU AU2023265523A patent/AU2023265523A1/en active Pending
- 2023-05-04 JP JP2024564932A patent/JP2025516315A/ja active Pending
- 2023-05-04 CA CA3251997A patent/CA3251997A1/en active Pending
- 2023-05-04 CN CN202380050874.5A patent/CN119487033A/zh active Pending
- 2023-05-04 WO PCT/US2023/020978 patent/WO2023215465A1/en not_active Ceased
- 2023-05-04 US US18/862,727 patent/US20250288588A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4519268A1 (en) | 2025-03-12 |
| JP2025516315A (ja) | 2025-05-27 |
| WO2023215465A1 (en) | 2023-11-09 |
| US20250288588A1 (en) | 2025-09-18 |
| CA3251997A1 (en) | 2023-11-09 |
| AU2023265523A1 (en) | 2024-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6602802B2 (ja) | Ｓｓａｏの置換３−ハロアリルアミン阻害剤およびその使用 | |
| US12065412B2 (en) | CFTR regulators and methods of use thereof | |
| EP2163548A1 (en) | Prophylactic or therapeutic agent for age-related macular degeneration | |
| JP7222042B2 (ja) | ５′－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法 | |
| JP2023512828A (ja) | クロマカリムプロドラッグ療法のための改善された方法及び組成物 | |
| EP2251009B1 (en) | Prophylactic or therapeutic agent for ocular disease accompanied by optic nerve disorder | |
| US20230017597A1 (en) | 8-substituted styryl xanthine derivatives and uses thereof | |
| CA3005527C (fr) | Mirabegron pour le traitement de maladies retiniennes | |
| US20250288588A1 (en) | Substituted imidazopyridines and imidazopyrimidines, and use of same for treating, ameliorating, and/or preventing retinal degeneration | |
| WO1995007282A1 (en) | Depression remedy | |
| CN112010818B (zh) | 吗啉酰胺衍生物及其用途 | |
| US20240043396A1 (en) | Methods of treating ocular fibrotic pathologies | |
| WO2025199211A1 (en) | Imidazopyridines and imidazopyrimidines, and methods of using same | |
| KR101896398B1 (ko) | 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물 | |
| US20240285623A1 (en) | Trpa1 channel antagonist compound for use in degenerative retinal diseases | |
| WO2009110526A1 (ja) | ３’，５－ジ－２－プロペニル－（１，１’－ビフェニル）－２，４’－ジオールを有効成分として含有する視神経障害の予防又は治療剤 | |
| CN102215842A (zh) | 含有吡啶-3-甲醛o-(哌啶-1-基-丙基)-肟衍生物作为有效成分的脉络膜视网膜变性疾病的治疗剂 | |
| TW202438074A (zh) | 噁二唑衍生物化合物及包含其之醫藥組合物 | |
| HK40073052A (en) | Medical use of 5'-adenosine diphosphate ribose (adpr) | |
| CN118591529A (zh) | 氘代rock抑制剂、药物组合物和治疗应用 | |
| WO2024044813A1 (en) | Novel selective inhibitors of lysyl oxidases | |
| KR20170095850A (ko) | 각막 상피 장애 치료제 | |
| HK1245237B (en) | Substituted 3-haloallylamine inhibitors of ssao and uses thereof | |
| RU2007112885A (ru) | Способ лечения глазных заболеваний | |
| WO2015065136A1 (ko) | 마시티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 예방 또는 치료용 약학적 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |